Neuropeptide Receptor Targeted Therapeutics for the Treatment of Endocrine Diseases and Cancers. Crinetics is driven by a passion for drug-hunting and tempered by a post-recession startup culture. The goal is to create new therapeutics that can make a meaningful difference in the lives of our patients.

Crinetics Pharmaceuticals

Technology

United States of America

The technology floor hosts companies that produce software, hardware, semiconductor equipment, or companies that provide internet related services. Technology trends that will grow this year include artificial intelligence, cloud computing, blockchain, big data, and apps.  The technology sector is often the most attractive investment destination in any economy.  Some of the technological megatrends such as drones, autonomous vehicles, blockchain, artificial intelligence, augmented and virtual reality will continue to endlessly grow in the foreseeable future.

Irvine

California

San Diego

51-200 Employees

In this installment of The Voices of Acromegaly, hear from patients about the importance of being your own advocate when it ...

Acromegaly Patient Videos: Be Your Own Advocate

Crinetics discusses the positive results from the multiple-ascending dose cohorts of the CRN04777 Phase 1 clinical study that ...

CRN04777: Phase 1 Multiple Ascending Dose (MAD) Preliminary Results

Hear from Dr. Alan S. Krasner, M.D., the Chief Medical Officer at Crinetics Pharmaceuticals, about his work designing new clinical ...

Crinetics Staff Profile: Dr. Alan S. Krasner

Dr. Hjalmar Lagast talks about Crinetics' paltusotine phase 2 study in carcinoid syndrome and presents "Dose selection for ...

NANETS 2021 - Paltusotine for the Treatment of Patients With Carcinoid Syndrome

Hear from Dr. Alessandra Casagrande, M.D., Ph.D., a Medical Science Director at Crinetics. Hear about her career, what excites ...

Crinetics Staff Profile: Dr. Alessandra Casagrande

What's it like to have a rare disease? How does it affect your life and that of your loved ones? We asked a few people to share ...

Rare Disease Day Patients' Perspectives

The H.C. Wainwright Global Investment Conference features presentations by companies in healthcare and biotech, technology, ...

H.C. Wainwright 23rd Annual Global Investment Conference

Crinetics discusses the positive results from the multiple-ascending dose cohorts of the CRN04894 Phase 1 clinical study that ...

CRN04894: Phase 1 Multiple Ascending Dose (MAD) Preliminary Results

Crinetics Pharmaceuticals' founder and CEO, Scott Struthers, Ph.D. gives Corporate Presentation at the 41st annual J.P. Morgan, ...

Top Videos about Crinetics Pharmaceuticals Careers